Glutamine pathway helps dormant prostate cancer cells survive and recur

A quiet biochemical switch may explain why prostate cancer can return years after treatment appears to have succeeded. New research points to glutamine synthesis—the cellular production of the amino acid glutamine—as a critical lifeline that allows dormant tumor cells to survive harsh conditions and later reawaken to drive recurrence. The findings, published in Cell Death & Discovery, add a metabolic dimension to the long-standing puzzle of minimal residual disease in prostate cancer, one of the most common malignancies in men worldwide.

The study, led by Zhao, Meng, Zhou and colleagues, focuses on a phenomenon that has long frustrated oncologists: tumor dormancy. In many patients with prostate cancer, surgical removal of the prostate or radiation therapy eliminates the detectable tumor, yet microscopic pockets of cancer cells remain in the body. These residual cells can enter a state of deep quiescence, halting their division and effectively hiding from therapies such as chemotherapy and androgen-deprivation treatment, both of which preferentially kill rapidly proliferating cells. Years or even decades later, some of these dormant cells reactivate, seed new lesions, and give rise to incurable metastatic disease. Understanding how dormant cells stay alive during this hidden phase has therefore become one of the most important questions in cancer biology.

The new work identifies glutamine metabolism as a central pillar of that survival strategy. Glutamine is the most abundant amino acid in human blood and serves as a versatile nitrogen donor, a building block for proteins and nucleotides, and a substrate for producing energy and antioxidant molecules. Although many cancer cells are famous for consuming glutamine at enormous rates—a hallmark known as glutamine addiction—the researchers found that dormant prostate cancer cells face the opposite problem. In their quiescent state, with limited access to external nutrients and diminished uptake from the tumor microenvironment, these cells rely on their own internal glutamine production to meet essential metabolic demands.

At the heart of this adaptation is glutamine synthetase, the enzyme that converts glutamate and ammonia into glutamine. The study shows that dormant tumor cells upregulate this synthetic pathway, essentially running the glutamine reaction in reverse compared with the consumption-oriented metabolism of aggressive, proliferating tumors. By manufacturing glutamine internally, the dormant cells maintain nitrogen balance, buffer toxic ammonia that accumulates in their environment, and sustain the synthesis of molecules needed for basic cellular upkeep. When the researchers interfered with this pathway, dormant cells lost their protective capacity: survival during dormancy declined, and the population of cells capable of later reawakening shrank dramatically.

The team used experimental models of prostate cancer designed to capture the biology of tumor dormancy and recurrence. By manipulating the expression of components of the glutamine synthesis pathway and tracking cell fate over time, they were able to link the metabolic program to both phases of the dormancy life cycle. Cells with active glutamine synthesis not only survived longer in a dormant state but also retained the ability to exit quiescence and re-enter the cell cycle, re-establishing proliferative tumors. In other words, the same metabolic adaptation that keeps dormant cells alive also appears to preserve their future potential to relapse.

A particularly striking aspect of the findings is the role of ammonia detoxification. Ammonia is generated continuously by cellular metabolism and, at high concentrations, is poisonous to cells. Proliferating tumors often export waste and draw on abundant blood-borne nutrients, but dormant micrometastases may sit in nutrient-poor niches where waste disposal is inefficient. Glutamine synthetase offers an elegant solution by incorporating ammonia directly into glutamine, converting a toxic byproduct into a usable metabolite. The study suggests that dormant prostate cancer cells exploit this reaction as both a detoxification mechanism and a nitrogen-recycling system, enabling long-term persistence in metabolically hostile territory.

The implications for prostate cancer treatment are considerable. Current adjuvant therapies aim primarily at killing dividing cells or blocking androgen receptor signaling, the main growth engine of prostate adenocarcinoma. Dormant cells, by definition, escape such approaches because they are not dividing and their signaling dependencies differ from those of active tumors. The new results suggest that targeting glutamine synthetase or related metabolic enzymes could specifically undermine the survival machinery of dormant cells, offering a strategy to prevent recurrence rather than simply treat it after the fact. In principle, a drug that disables the glutamine synthesis pathway could be administered after primary treatment to eliminate residual dormant disease before it has the chance to reawaken.

The research also adds to a growing appreciation of metabolic flexibility as a defining feature of cancer progression. Tumors are not metabolically static; they rewire their biochemistry in response to nutrient availability, oxygen levels, and therapeutic pressure. The shift from glutamine consumption to glutamine synthesis observed in this study illustrates how tumor cells can adopt nearly opposite metabolic strategies at different stages of their life cycle. This plasticity complicates the interpretation of imaging and biomarkers that assume uniform tumor metabolism, but it also opens new therapeutic windows, because enzymes that are dispensable in normal proliferating tissues may become vulnerabilities in dormant disease.

Questions remain before these findings can be translated into the clinic. The researchers’ experiments establish a causal role for the glutamine synthesis pathway in models of dormancy and recurrence, but the biology of human prostate cancer dormancy is likely to involve additional metabolic pathways, immune interactions, and niche-specific signals. Glutamine synthetase is also active in normal tissues such as the liver and brain, raising the challenge of achieving therapeutic selectivity. Nonetheless, the identification of a druggable metabolic node that supports dormant cell survival gives researchers a concrete target and a rationale for developing combination strategies that pair androgen-deprivation therapy with anti-metabolic agents.

The broader message of the study is that cancer recurrence is not a random event but the outcome of a programmed survival state with its own biochemical requirements. By revealing that dormant prostate cancer cells depend on making their own glutamine, the work reframes recurrence as a preventable metabolic process. If follow-up studies confirm these mechanisms in patients and lead to effective inhibitors of the dormant-cell survival program, the long tail of prostate cancer relapse could one day be shortened—or cut off entirely.